Gemphire Therapeutics Inc. (NASDAQ:GEMP) had its price target raised by Jefferies Group LLC to $32.00 in a research note issued to investors on Tuesday, August 1st, MarketBeat reports. The brokerage currently has a buy rating on the stock. Jefferies Group also issued estimates for Gemphire Therapeutics’ FY2018 earnings at ($1.87) EPS, FY2019 earnings at ($1.90) EPS, FY2020 earnings at ($1.38) EPS and FY2021 earnings at ($1.07) EPS.
Other research analysts have also issued research reports about the company. Zacks Investment Research upgraded Gemphire Therapeutics from a sell rating to a hold rating in a research report on Thursday, May 11th. Canaccord Genuity set a $31.00 target price on Gemphire Therapeutics and gave the stock a buy rating in a research note on Wednesday, July 26th. Finally, Piper Jaffray Companies initiated coverage on Gemphire Therapeutics in a research note on Monday, April 10th. They issued an overweight rating and a $30.00 target price for the company. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Gemphire Therapeutics presently has a consensus rating of Buy and an average target price of $24.33.
Gemphire Therapeutics (NASDAQ:GEMP) opened at 8.24 on Tuesday. The company’s market capitalization is $87.56 million. The firm has a 50-day moving average of $14.43 and a 200 day moving average of $11.57. Gemphire Therapeutics has a 12-month low of $7.20 and a 12-month high of $21.59.
Gemphire Therapeutics (NASDAQ:GEMP) last issued its quarterly earnings results on Monday, August 14th. The company reported ($0.99) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.71) by $0.28. Analysts forecast that Gemphire Therapeutics will post ($2.98) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Jefferies Group LLC Increases Gemphire Therapeutics Inc. (NASDAQ:GEMP) Price Target to $32.00” was originally published by BNB Daily and is owned by of BNB Daily. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at https://www.baseball-news-blog.com/2017/08/19/jefferies-group-llc-increases-gemphire-therapeutics-inc-nasdaqgemp-price-target-to-32-00-updated-updated.html.
A number of large investors have recently bought and sold shares of the company. Cambridge Investment Research Advisors Inc. boosted its stake in Gemphire Therapeutics by 1.7% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 153,064 shares of the company’s stock valued at $1,959,000 after buying an additional 2,500 shares during the last quarter. Norris Perne & French LLP MI purchased a new position in Gemphire Therapeutics during the first quarter valued at approximately $110,000. Advisory Services Network LLC purchased a new position in Gemphire Therapeutics during the second quarter valued at approximately $139,000. Renaissance Technologies LLC purchased a new position in Gemphire Therapeutics during the first quarter valued at approximately $184,000. Finally, Vanguard Group Inc. raised its position in Gemphire Therapeutics by 137.6% in the second quarter. Vanguard Group Inc. now owns 30,898 shares of the company’s stock valued at $399,000 after buying an additional 17,892 shares during the period. Hedge funds and other institutional investors own 28.18% of the company’s stock.
Gemphire Therapeutics Company Profile
Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.
Receive News & Ratings for Gemphire Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.